ImmunityBio, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 11, 2024, details the results of ImmunityBio, Inc.'s Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol IBRX.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
On June 11, 2024, approximately 90% of outstanding shares (609,540,014 of 677,036,411) were represented at the Annual Meeting, establishing a quorum. The following matters were approved:
- Election of Directors: All nine nominees were re-elected for one-year terms. Patrick Soon-Shiong, M.D., received the highest number of "For" votes (556,206,355), while Barry J. Simon, M.D., received the lowest (559,237,600). Withheld votes ranged from approximately 917,000 to 6.4 million per nominee.
- Equity Plan Amendment: Stockholders approved an amendment to increase the number of shares authorized for issuance under the 2015 Equity Incentive Plan by 19,900,000 shares. The vote was 547,258,257 "For" versus 12,472,068 "Against."
- Say-on-Pay: The advisory vote to approve Named Executive Officer compensation for the fiscal year ended December 31, 2023, passed with 556,683,366 "For" votes and 2,530,858 "Against" votes.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 606,920,437 "For" votes.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the impact of the 19,900,000 share increase to the 2015 Equity Incentive Plan on potential future dilution.
- Confirm the re-election of the board, noting that all nine directors were approved with significant majorities.
- Review the full proxy statement filed on April 29, 2024, for detailed executive compensation data referenced in the Say-on-Pay vote.
- Note that the filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial health metrics.